New modular implants aim to rebuild bones lost to cancer or injury
NCT ID NCT07369778
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a new line of massive prosthetic implants (the Pantheon range) in 375 people who have lost large amounts of bone due to cancer, complex fractures, or failed previous surgeries. The implants are designed to restore function quickly and stay stable long-term. Researchers will track how long the implants last without needing revision and how patients' quality of life changes over five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pantheon range massive prosthetic implants (including PFR, DFR, PTR, TFR, hybrid connectors, custom-made implants)
- What this could lead to
- If successful, this could confirm that these modular implants provide long-lasting, stable reconstruction for people with severe bone loss, improving mobility and quality of life.
- What could go wrong
- This is an early-stage observational study with no control group, so results may not prove superiority over existing options. Implants can fail over time, requiring revision surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASSIVE BONE LOSS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes
Nantes, 44093, France